As a payer, Brian B. Kiss, MD, vice president, healthcare transformation, Blue Cross Blue Shield of Florida, acknowledges that benefit design is complex and the benefit structure for end-of-life care can be funded differently. “We’re working on the system to make these decisions,” he says. Plan designs are shifting toward out-of-pocket maximums; a patient receiving chemotherapy treatment will almost certainly reach that maximum cost-sharing limit, and possibly after only 1 month of therapy.
“The benefit design is a nightmare,” states Bruce A. Feinberg, DO, vice president and chief medical officer of Cardinal Health Specialty Solutions. Frequently, benefit design does not take the personalized aspect of medicine into account, which is so important in palliative care. It is important that benefit design alleviates the problem, he adds.
Dr Kiss believes that we need benefit designs that will not hinder patients from taking oral oncolytics or filling a prescription. It is important to have a value-based benefit design that motivates patients to do the right thing for themselves, notes Dr Kiss, and this is even more critical in palliative care. There should be as little obstruction as possible for patients to fill that prescription or take that full prescribed dose.
As payers we need to address some of those structural issues and that may mean “looking at changing and moving to value-based benefit design,” says Dr Kiss.
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Contributor: For Complex Cases, Continuity in Acute Care Is Necessary
April 23rd 2025For patients with complex needs and social challenges like unstable housing, the hospital has become their de facto medical home—yet each visit is a fragmented restart, without continuity, context, or a clear path forward.
Read More